1. |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J National Cancer Center, 2022, 2(1): 1-9.
|
2. |
曾勇, 谢坤林. 肝癌全程管理模式. 中国实用外科杂志, 2021, 41(3): 343-347.
|
3. |
四川大学华西医院肝癌MDT团队. 肝细胞肝癌全程多学科规范化管理: 华西医院多学科专家共识 (第二版). 中国普外基础与临床杂志, 2020, 27(9): 1062-1077.
|
4. |
Vietti Violi N, Gnerre J, Law A, et al. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. Eur Radiol, 2022, 32(9): 6493-6503.
|
5. |
Yoon J, Lee S, Shin J, et al. LI-RADS version 2018 treatment response algorithm: diagnostic performance after transarterial radioembolization for hepatocellular carcinoma. Korean J Radiol, 2021, 22(8): 1279-1288.
|
6. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中华消化外科杂志, 2020, 19(1): 1-20.
|
7. |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识 (2021版). 中华消化外科杂志, 2021, 20(6): 600-616.
|
8. |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol, 2019, 37(24): 2141-2151.
|
9. |
Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol, 2020, 21(7): 947-956.
|
10. |
Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends, 2021, 15(3): 155-160.
|
11. |
张晓赟, 朱心睿, 彭伟, 等. 经肝动脉化疗栓塞+仑伐替尼+PD-1单抗在中晚期不可切除肝癌转化切除中的安全性和有效性的前瞻性队列研究: 初步报告. 中国普外基础与临床杂志, 2022, 29(1): 39-45.
|
12. |
Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
|
13. |
Qu WF, Ding ZB, Qu XD, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open, 2022, 6(5): zrac114. doi: 10.1093/bjsopen/zrac114.
|
14. |
Song T, Lang M, Ren S, et al. The past, present and future of conversion therapy for liver cancer. Am J Cancer Res, 2021, 11(10): 4711-4724.
|
15. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南 (2022年版). 中华消化外科杂志, 2022, 21(2): 143-168.
|
16. |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
|
17. |
Huang L, Li GM, Zhu JY, et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. Onco Targets Ther, 2012, 5: 457-462.
|
18. |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs, 2011, 29(6): 1360-1369.
|
19. |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2015, 16(13): 1344-1354.
|
20. |
Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant, 2018, 32(5): e13246. doi: 10.1111/ctr.13246.
|
21. |
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol, 2013, 59(6): 1193-1199.
|
22. |
Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg, 2020, 272(5): 855-862.
|
23. |
Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl, 2012, 18(1): 62-69.
|